Back to top
more

Avid Bioservices (CDMO)

(Delayed Data from NSDQ)

$10.27 USD

10.27
494,093

+0.31 (3.11%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $10.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Avid Bioservices (CDMO) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 25.00% and 23.74%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for November 7th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

New Strong Sell Stocks for October 8th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Why Avid Bioservices (CDMO) Could Be Positioned for a Slump

by Zacks Equity Research

Avid Bioservices (CDMO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Avid Bioservices (CDMO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of -166.67% and 5.56%, respectively, for the quarter ended July 2019. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 28.57% and 2.65%, respectively, for the quarter ended January 2019. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and -5.32%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Avid Bioservices (CDMO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options

by Zacks Equity Research

Avid Bioservices (CDMO) needs investors to pay close attention to the stock based on moves in the options market lately.

Avid Bioservices (CDMO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 26.52%, respectively, for the quarter ended July 2018. Do the numbers hold clues to what lies ahead for the stock?

    Avid Bioservices (CDMO) Q1 Earnings Preview: Here's What to Look Out For

    by Zacks Equity Research

    Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Avid Bioservices, Mellanox, Berkshire Hathaway, Intel and Chevron highlighted as Zacks Bull and Bear of the Day

      by Zacks Equity Research

      Avid Bioservices, Mellanox, Berkshire Hathaway, Intel and Chevron highlighted as Zacks Bull and Bear of the Day

        Avid Bioservices (CDMO) Reports Q4 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Avid Bioservices (CDMO) delivered earnings and revenue surprises of 6.67% and 6.65%, respectively, for the quarter ended April 2018. Do the numbers hold clues to what lies ahead for the stock?

          Options Traders Expect Huge Moves in Avid Bioservices (CDMO) Stock

          by Zacks Equity Research

          Avid Bioservices (CDMO) needs investors to pay close attention to the stock based on moves in the options market lately.